Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study

Agid, 2013, Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010, Am. J. Psychiatry, 170, 1335, 10.1176/appi.ajp.2013.12030315 2000 Andreasen, 2005, Remission in schizophrenia: proposed criteria and rationale for consensus, Am. J. Psychiatr., 162, 441, 10.1176/appi.ajp.162.3.441 Buchanan, 2007, Persistent negative symptoms in schizophrenia: an overview, Schizophr. Bull., 33, 1013, 10.1093/schbul/sbl057 Cassidy, 2010, Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years, Schizophr. Bull., 36, 1001, 10.1093/schbul/sbp007 Chakos, 2006, Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial, Psychiatr. Serv., 57, 1094, 10.1176/ps.2006.57.8.1094 Chang, 2011, Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study, Schizophr. Res., 133, 22, 10.1016/j.schres.2011.09.006 Chue, 2014, Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options, Neuropsychiatr. Dis. Treat., 10, 777, 10.2147/NDT.S43404 Csernansky, 2002, Relapse and rehospitalisation rates in patients with schizophrenia, CNS Drugs, 16, 473, 10.2165/00023210-200216070-00004 Doering, 1998, Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder, Schizophr. Bull., 24, 87, 10.1093/oxfordjournals.schbul.a033316 Dold, 2015, Increasing placebo response in antipsychotic trials: a clinical perspective, Evid. Based Ment. Health, 18, 77, 10.1136/eb-2015-102098 Emsley, 2011, The concepts of remission and recovery in schizophrenia, Curr. Opin. Psychiatry, 24, 114 Fervaha, 2014, Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study, Eur. Neuropsychopharmacol., 24, 1078, 10.1016/j.euroneuro.2014.03.001 Fervaha, 2014, Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia, Acta Psychiatr. Scand., 130, 290, 10.1111/acps.12289 Häfner, 2015, What is schizophrenia? 25 years of research into schizophrenia - the age beginning course study, World J. Psychiatry., 5, 167, 10.5498/wjp.v5.i2.167 Haro, 2015, Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study, Schizophr. Res., 169, 234, 10.1016/j.schres.2015.09.001 Haro, 2006, Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study, J. Clin. Psychopharmacol., 26, 571, 10.1097/01.jcp.0000246215.49271.b8 Haro, 2003, The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment, Acta Psychiatr. Scand., 7, 10.1034/j.1600-0447.107.s416.4.x Haro, 2003, The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment, Acta Psychiatr. Scand., 107, 222, 10.1034/j.1600-0447.2003.00064.x Haro, 2003, The clinical global impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia, Acta Psychiatr. Scand., 16, 10.1034/j.1600-0447.107.s416.5.x Harrow, 2005, Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study, Schizophr. Bull., 31, 723, 10.1093/schbul/sbi026 Hegarty, 1994, One hundred years of schizophrenia: a meta-analysis of the outcome literature, Am. J. Psychiatry, 151, 1409, 10.1176/ajp.151.10.1409 Hoffman, 1994, Age and other factors relevant to the rehospitalization of schizophrenic outpatients, Acta Psychiatr. Scand., 89, 205, 10.1111/j.1600-0447.1994.tb08093.x Iasevoli, 2016, Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones, Prog. Neuropsychopharmacol. Biol. Psychiatry, 65, 34, 10.1016/j.pnpbp.2015.08.010 Jaaskelainen, 2015, Twenty years of schizophrenia research in the Northern Finland Birth Cohort 1966: a systematic review, Schizophr. Res. Treat., 2015 Jordan, 2014, The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis, J. Clin. Psychiatry, 75, e566, 10.4088/JCP.13m08606 Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 Liddle, 1987, Schizophrenic syndromes, cognitive performance and neurological dysfunction, Psychol. Med., 17, 49, 10.1017/S0033291700012976 Malla, 1993, Three syndrome concept of schizophrenia. A factor analytic study, Schizophr. Res., 10, 143, 10.1016/0920-9964(93)90049-O Marder, 1997, The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials, J. Clin. Psychiatry, 58, 538, 10.4088/JCP.v58n1205 McGrath, 2008, Schizophrenia: a concise overview of incidence, prevalence, and mortality, Epidemiol. Rev., 30, 67, 10.1093/epirev/mxn001 Menezes, 2006, A systematic review of longitudinal outcome studies of first-episode psychosis, Psychol. Med., 36, 1349, 10.1017/S0033291706007951 Milev, 2005, Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up, Am. J. Psychiatry, 162, 495, 10.1176/appi.ajp.162.3.495 Morosini, 2000, Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning, Acta Psychiatr. Scand, 101, 323, 10.1111/j.1600-0447.2000.tb10933.x Norman, 2001, Duration of untreated psychosis and cognitive functioning in first-episode patients, Br. J. Psychiatry, 179, 340, 10.1192/bjp.179.4.340 Norman, 1999, Symptoms and cognition as predictors of community functioning: a prospective analysis, Am. J. Psychiatry, 156, 400, 10.1176/ajp.156.3.400 Novick, 2009, Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study, Schizophr. Res., 108, 223, 10.1016/j.schres.2008.11.007 Novick, 2007, Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study, Psychopharmacology, 191, 1015, 10.1007/s00213-007-0730-2 Owen, 2016, Schizophrenia, Lancet, 388, 86, 10.1016/S0140-6736(15)01121-6 Postrado, 1995, Quality of life and clinical predictors of rehospitalization of persons with severe mental illness, Psychiatr. Serv., 46, 1161, 10.1176/ps.46.11.1161 Rabinowitz, 2012, Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data, Schizophr. Res., 137, 147, 10.1016/j.schres.2012.01.015 Robinson, 2004, Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder, Am. J. Psychiatry., 161, 473, 10.1176/appi.ajp.161.3.473 Robinson, 1999, Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Arch. Gen. Psychiatry, 56, 241, 10.1001/archpsyc.56.3.241 Rutherford, 2014, Placebo response in antipsychotic clinical trials: a meta-analysis, JAMA Psychiatry, 71, 1409, 10.1001/jamapsychiatry.2014.1319 San, 2013, Factors associated with relapse in patients with schizophrenia, Int. J. Psychiatry. Clin. Pract., 17, 2, 10.3109/13651501.2012.687452 Stahl, 2004, A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation, Curr. Med. Chem., 11, 313, 10.2174/0929867043456070 Strauss, 2008, Periods of recovery in deficit syndrome schizophrenia: a 20-year multi–follow-up longitudinal study, Schizophr. Bull., 36, 788, 10.1093/schbul/sbn167 Suzuki, 2014, A review on schizophrenia and relapse – a quest for user-friendly psychopharmacotherapy, Hum. Psychopharmacol., 29, 414, 10.1002/hup.2421 Suzuki, 2012, Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation, Psychiatry Res., 197, 1, 10.1016/j.psychres.2012.02.013 Suzuki, 2011, Treatment resistant schizophrenia and response to antipsychotics: a review, Schizophr. Res., 133, 54, 10.1016/j.schres.2011.09.016 Tajima-Pozo, K., de Castro Oller, M.J., Lewczuk, A., Montañes-Rada, F., 2015. Understanding the direct and indirect costs of patients with schizophrenia. Version 2. F1000Res. 4, 182. Group, 1990, EuroQol – a EuroQol-a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9 Ventura, 2015, Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later, Schizophr. Res., 161, 407, 10.1016/j.schres.2014.10.043 Ventura, 2011, Remission and recovery during the first outpatient year of the early course of schizophrenia, Schizophr. Res., 132, 18, 10.1016/j.schres.2011.06.025 White, 2009, Predictors of 10-year outcome of first-episode psychosis, Psychol. Med., 39, 1447, 10.1017/S003329170800514X Wilkinson, 2000, Self-report quality of life measure for people with schizophrenia: the SQLS, Br. J. Psychiatr., 177, 42, 10.1192/bjp.177.1.42 Zink, 2016, Schizophrenia treatment: an obstacle course, Lancet Psychiatry, 3, 310, 10.1016/S2215-0366(16)00023-7 Zink, 2015, Glutamatergic agents for schizophrenia: current evidence and perspectives, Expert Rev. Clin. Pharmacol., 8, 335, 10.1586/17512433.2015.1040393